ATHA
Athira Pharma Inc

2,395
Loading...
Loading...
News
all
press releases
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's treatment fosgonimeton, with data showing directional improvements but no...
Benzinga·1y ago
News Placeholder
More News
News Placeholder
Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)
Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ...
PR Newswire·1y ago
News Placeholder
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Presentation to highlight therapeutic potential of Athira's small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease...
Globe Newswire·2y ago
News Placeholder
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Stryker (SYK) one of those stocks right now? A quick glance at the company's...
Zacks Investment Research·2y ago
News Placeholder
Athira Pharma (ATHA, $3.58) entered Downtrend as Momentum indicator drops below 0 level on Mar 08, 2024
This indicator may be signaling that ATHA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Tickeron - Stocks·2y ago
News Placeholder
Athira Pharma Shares Slide
Athira Pharma, Inc. (ATHA) shares are declining more than 3 percent on Friday morning trade after reaching a new year-to-date high at Thursday's close. There have been no stock-specific news today...
RTT News - Momentum Stocks·2y ago
News Placeholder
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference
Data adds to increasing body of evidence supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative diseases such as Parkinson's disease...
Globe Newswire·2y ago
News Placeholder
Athira Pharma reports FY23 EPS ($3.09), consensus ($3.33)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease; topline data expected in second half of 2024 On track...
Globe Newswire·2y ago
News Placeholder
Athira Pharma (ATHA, $3.71) RSI Indicator left the overbought zone on February 21, 2024
This is a signal that ATHA's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...
Tickeron - Stocks·2y ago

Latest ATHA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.